Gene: EPHA7
Official Full Name: EPH receptor A7provided by HGNC
Gene Summary: This gene belongs to the ephrin receptor subfamily of the protein-tyrosine kinase family. EPH and EPH-related receptors have been implicated in mediating developmental events, particularly in the nervous system. Receptors in the EPH subfamily typically have a single kinase domain and an extracellular region containing a Cys-rich domain and 2 fibronectin type III repeats. The ephrin receptors are divided into 2 groups based on the similarity of their extracellular domain sequences and their affinities for binding ephrin-A and ephrin-B ligands. Increased expression of this gene is associated with multiple forms of carcinoma. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Dec 2013]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO38016 | EPHA7 Knockout cell line (HeLa) | Human | EPHA7 | 1:3~1:6 | Negative | Online Inquiry |
KO38017 | EPHA7 Knockout cell line (HEK293) | Human | EPHA7 | 1:3~1:6 | Negative | Online Inquiry |
EPHA7 Gene Knockout Cell Lines are sophisticated biological tools that allow for the targeted study of the EPHA7 gene's role in various cellular processes. The EPHA7 gene encodes a member of the ephrin receptor family, which plays a critical role in developmental processes, such as neurogenesis, as well as in pathological conditions like cancer. These knockout cell lines have been engineered using CRISPR/Cas9 technology to create loss-of-function mutations, enabling researchers to examine the functional consequences of EPHA7's absence in a controlled environment.
The primary function of these cell lines is to facilitate in-depth investigations into the molecular mechanisms regulated by EPHA7, including cell migration, proliferation, and differentiation. By observing the differences between wild-type and EPHA7 knockout cells, researchers can uncover insights into the pathways influenced by this gene and how its dysregulation may contribute to diseases. This product is particularly significant in cancer research where the role of cell signaling pathways is crucial for understanding tumor progression and metastasis.
What sets the EPHA7 Gene Knockout Cell Lines apart from alternative products is the precision of the CRISPR/Cas9 technology used in their development, which ensures a clean knockout with minimal off-target effects. Additionally, these cell lines come with extensive characterization data and robust quality control measures, ensuring reproducibility and reliability in experimental results.
Researchers, clinicians, and pharmaceutical companies will find immense value in utilizing these knockout cell lines for their drug discovery programs, biomarkers identification, and functional genomics studies. The clarity of results derived from these models can expedite the understanding of disease mechanisms and the development of novel therapeutic interventions.
Our company possesses extensive experience in genetic engineering and cell line development, leveraging cutting-edge technology and rigorous quality standards to provide researchers with reliable biological products. Our commitment to innovation in the field ensures that the EPHA7 Gene Knockout Cell Lines are not only valuable research tools but also integral components of advancing biomedical science.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.